BR0209863A - Composição catártica - Google Patents

Composição catártica

Info

Publication number
BR0209863A
BR0209863A BR0209863-6A BR0209863A BR0209863A BR 0209863 A BR0209863 A BR 0209863A BR 0209863 A BR0209863 A BR 0209863A BR 0209863 A BR0209863 A BR 0209863A
Authority
BR
Brazil
Prior art keywords
cathartic
composition
cathartic composition
bioactive
alleviating
Prior art date
Application number
BR0209863-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BR0209863A publication Critical patent/BR0209863A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BR0209863-6A 2001-05-18 2002-05-17 Composição catártica BR0209863A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29163501P 2001-05-18 2001-05-18
PCT/JP2002/004768 WO2002094274A1 (en) 2001-05-18 2002-05-17 Cathartic composition

Publications (1)

Publication Number Publication Date
BR0209863A true BR0209863A (pt) 2004-06-08

Family

ID=23121127

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209863-6A BR0209863A (pt) 2001-05-18 2002-05-17 Composição catártica

Country Status (18)

Country Link
US (2) US6956056B2 (enExample)
EP (1) EP1389116B1 (enExample)
JP (1) JP4597481B2 (enExample)
KR (1) KR100867295B1 (enExample)
CN (1) CN1273140C (enExample)
AR (3) AR035242A1 (enExample)
AT (1) ATE387204T1 (enExample)
AU (1) AU2002307725B2 (enExample)
BR (1) BR0209863A (enExample)
CA (1) CA2445651C (enExample)
DE (1) DE60225266T2 (enExample)
DK (1) DK1389116T3 (enExample)
ES (1) ES2301681T3 (enExample)
MX (1) MXPA03010510A (enExample)
NZ (1) NZ529406A (enExample)
PT (1) PT1389116E (enExample)
TW (2) TWI324589B (enExample)
WO (1) WO2002094274A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
US7049319B2 (en) 2003-09-23 2006-05-23 Semaan Abboud Colon cleansing composition and method
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US20070071793A1 (en) * 2005-09-23 2007-03-29 Leon Clark Cure for prostate enlargement frequency of urination and cancer
CA2819844C (en) * 2006-02-07 2015-09-15 R-Tech Ueno, Ltd. Prostaglandin derivatives
CN102050808B (zh) * 2009-11-02 2014-03-12 上海天伟生物制药有限公司 一种前列腺素中间体的制备方法
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
US10457623B1 (en) * 2018-07-13 2019-10-29 Chirogate International Inc. Process for the preparation of Lubiprostone and intermediates thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1396206A (en) * 1972-04-27 1975-06-04 Upjohn Co Prostaglandins and the preparation thereof
ZA744581B (en) * 1973-07-20 1975-07-30 Upjohn Co Prostoglandin analogs
US3969376A (en) * 1973-07-20 1976-07-13 The Upjohn Company 13,14-Dihydro-16-fluoro prostaglandin E1 analogs
US3969381A (en) * 1975-02-21 1976-07-13 The Upjohn Company 13,14-Dihydro-16-fluoro prostaglandin B1 analogs
US3969379A (en) * 1975-02-21 1976-07-13 The Upjohn Company 13,14-Dihydro-16-fluoro prostaglandin A1 analogs
GB8305697D0 (en) * 1983-03-02 1983-04-07 Erba Farmitalia Pharmaceutical compositions
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
JP3187438B2 (ja) * 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers

Also Published As

Publication number Publication date
DE60225266D1 (de) 2008-04-10
AR098744A2 (es) 2016-06-08
CA2445651C (en) 2011-08-09
CA2445651A1 (en) 2002-11-28
US7459583B2 (en) 2008-12-02
DK1389116T3 (da) 2008-06-23
EP1389116A1 (en) 2004-02-18
TWI320711B (en) 2010-02-21
PT1389116E (pt) 2008-04-11
JP4597481B2 (ja) 2010-12-15
KR100867295B1 (ko) 2008-11-06
EP1389116B1 (en) 2008-02-27
CN1273140C (zh) 2006-09-06
US6956056B2 (en) 2005-10-18
WO2002094274A1 (en) 2002-11-28
TW200944210A (en) 2009-11-01
CN1509176A (zh) 2004-06-30
ATE387204T1 (de) 2008-03-15
KR20040020055A (ko) 2004-03-06
AR035242A1 (es) 2004-05-05
JP2004529960A (ja) 2004-09-30
AU2002307725B2 (en) 2008-07-10
AR110149A2 (es) 2019-02-27
US20030022933A1 (en) 2003-01-30
DE60225266T2 (de) 2009-03-19
NZ529406A (en) 2005-09-30
MXPA03010510A (es) 2004-03-02
US20050261375A1 (en) 2005-11-24
TWI324589B (en) 2010-05-11
ES2301681T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
BR0209863A (pt) Composição catártica
BR9911440A (pt) Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa
BR9814327A (pt) Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
BR0008911A (pt) Bactérias patogênicas da cepa lactobacillus para a prevenção de diarréia
BR9807076A (pt) Tratamento de esclerose múltipla mediante ingestão ou inalação de copolìmero-1
ES2131322T3 (es) Derivados terpenicos polialcoxilos y composiciones que los contienen.
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0212374A (pt) Oxintomodulina para a prevenção ou para o tratamento do excesso de peso
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
DK1455605T3 (da) Læskedrikerstatning
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
CA2224528A1 (fr) Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
WO2000015205A3 (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
BR0107157A (pt) Diagnose e tratamento de condições cardiovasculares
BR9915800A (pt) Produto terapêutico para supressão dos ruìdos de ronco
BR9814885A (pt) Combinação de um inibidor da enzima de conversão da angiotensina e de um diurético para o tratamento das desordens microcirculatórias
WO2003004039A3 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
BR0205812A (pt) Benzimidazois úteis no tratamento da disfunção sexual
BR0009595A (pt) Composição lìquida ou congelada e utilizaçãoterapêutica ou profilática da mesma
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
SE8904354D0 (sv) A pharmaceutical composition
BR9507437A (pt) Base livre de halofantrina e composições para o tratamento da malária
BR9812780A (pt) 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]